Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny, released on Thursday.
The company plans to produce part of the vaccine at its Czech plant, which will give the country access to the product once it is approved, the paper cited Erck as saying.
Novavax said on Monday it had begun enrolling volunteers for the second phase of an ongoing clinical trial of its COVID-19 vaccine candidate, with interim data expected in the fourth quarter of 2020.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled" What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine Found No Proof Of Covid Vaccine Causing Sudden Death, Says Top Medical Body 9 Dead, 2,800 Hurt As Pagers Explode Across Lebanon, Hezbollah Blames Israel IndiGo Flight Tailstrike Leaves Huge Dent During Take-Off From Delhi Airport 'Pager Bombs' Target Hezbollah In Lebanon. What We Know So Far - 5 Points World's Oldest Sunday Newspaper, 'The Observer', Up For Sale PM Modi To Visit US For Quad Summit, Attend UN Assembly From Sept 21-24 Ground Report: Central Forces' Canteens Open To Public In Violence-Hit Manipur Track Latest News Live on NDTV.com and get news updates from India and around the world.